NCT00102609View on ClinicalTrials.gov

A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

October 31, 2007

Conditions
Soft Tissue SarcomaSarcomaNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms
Interventions
DRUG

Doxorubicin

Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1

DRUG

Trabectedin

Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles

DRUG

Dexamethasone

Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin

Sponsors

Collaborators (2)

PharmaMar
PharmaMar S.A.U.
All Listed Sponsors
collaborator

PharmaMar

INDUSTRY

collaborator

PharmaMar S.A.U.

UNKNOWN

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY